TNFRSF13B and infection: Although promising results were reported in SLE in early trials with atacicept, an IgG1 Fc–TACI fusion protein that binds BAFF and APRIL to inhibit TACI signaling, larger trials reported no clinical effect and increased risk of infection [241,242,243].